MSH and Partners Explore Sustainability of Seasonal Malaria Chemoprevention
Douglas Keene, MSH Vice President of the Pharmaceuticals and Health Technologies, participated on a high-level panel of dignitaries and experts at an international symposium to deliberate the key dimensions of sustainability for seasonal malaria chemoprevention.
The symposium, held in London on June 9, was hosted by the Malaria Consortium through funding from UNITAID and was designed to examine key achievements and lessons learned from the first year of implementation of the Achieving Catalytic Expansion to Seasonal Malaria Chemoprevention project and to discuss assumptions on cost drivers and sustainability.
MSH Health Economist David Collins delivered a presentation on the return on investment of seasonal malaria chemoprevention. This launched the “Ensuring the Sustainability of Seasonal Malaria Chemoprevention” panel discussion with panelists including the Honorable Minister of States for Health, Nigeria and senior representation from MSH, the Global Fund, the Department of International Development, UNICEF, Medicines for Malaria Venture, Catholic Relief Services and the Malaria Consortium.
Together panelists and participants from various sectors—including public sector, Ministry of Health representatives, NGOs, bilateral and multilateral donors and agencies, academic institutions, private companies and foundations—placed seasonal malaria chemoprevention within a broader discussion about health system strengthening and health investments and discussed the economic impact of seasonal malaria chemoprevention and its sustainability in the region. The symposium participants formulated recommendations on how to examine further opportunities for seasonal malaria chemoprevention in terms of innovative delivery and scope, as well as the possibilities of integration with other public health interventions.